As an integrated service vendor of China pharmaceutical industry, Austar PharmMed Consumable Limited ("Austar") completed the transaction with Financiere Natexis Singapore 3 Pte. Ltd. ("Natexis") on July 29, 2005, under which Natexis invested US$13 million in its subscription of Series A preferred shares of Austar. Austar has over 300 big-sized pharmaceutical enterprises and research institutions as clients in China and also established several pharmaceutical enterprises in China. Llinks advised Austar on all respects of this transaction, including documentation, negotiation, and regulatory advice.